For the quarter ending 2026-03-31, STRO made $14,523K in revenue. -$38,484K in net income. Net profit margin of -264.99%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 14,523 | 11,647 | 9,693 | 63,745 |
| Research and development | 36,553 | 25,858* | 39,853 | 38,325 |
| General and administrative | 7,584 | 12,393* | 8,741 | 10,343 |
| Restructuring and related costs | 42 | 11,445* | 9,558 | 18,422 |
| Total operating expenses | 44,179 | 49,696 | 58,152 | 67,090 |
| Loss from operations | -29,656 | -38,049 | -48,459 | -3,345 |
| Interest income | 1,635 | 1,534 | 2,009 | 2,519 |
| Unrealized gain on equity securities | - | - | - | 0 |
| Non-cash interest expense related to the sale of future royalties | 9,467 | 9,547 | 9,670 | 9,647 |
| Interest and other income (expense), net | -1,011 | -775 | -737 | -1,044 |
| Loss before provision for income taxes | -38,499 | -46,828* | -56,857 | -11,517 |
| (benefit) from / provision for income taxes | -15 | -66* | 0 | -18 |
| Net loss | -38,484 | -46,762 | -56,857 | -11,499 |
| Basic EPS | -2.94 | 0.214 | -0.67 | -0.14 |
| Diluted EPS | -2.94 | 0.214 | -0.67 | -0.14 |
| Basic Average Shares | 13,082,355 | -218,564,810 | 84,869,864 | 84,580,125 |
| Diluted Average Shares | 13,082,355 | -218,564,810 | 84,869,864 | 84,580,125 |
SUTRO BIOPHARMA, INC. (STRO)
SUTRO BIOPHARMA, INC. (STRO)